Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Neurology and Rehabilitation Medicine



Genome Editing of Monogenic Neuromuscular Diseases

[1] Kevin, [1] Antonius

[1] Faculty of Medicine, Maranatha Christian University, Bandung City, West Java, Indonesia

Correspondence : dr.kevin827363@gmail.com

Article History :
Received date : 2024/07/28
Revised date : 2024/08/19
Accepted date : 2024/09/24
Published date : 2025/01/07

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The literature review presents a comprehensive analysis of the advancements and challenges in genome editing technologies, particularly focusing on CRISPR/Cas9, in the context of monogenic neuromuscular diseases such as Duchenne muscular dystrophy (DMD). **Literature Review:** The introduction outlines the urgency of developing effective treatments for DMD, a condition currently lacking approved therapies, and highlights the foundational work in gene delivery systems that has paved the way for innovative therapeutic strategies (L Maeder & A Gersbach, 2016). The review systematically discusses the transformative potential of CRISPR/Cas9 technology, emphasizing its efficiency and cost-effectiveness compared to traditional gene editing methods (Gaskell1 & Abualhaj2, 2018). The dual pathways for DNA repair—Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR)—are articulated, with the former often leading to unpredictable outcomes, while the latter offers more precise modifications, crucial for addressing genetic disorders (You et al., 2019). Moreover, the challenges posed by unique patient mutations and the necessity for optimized delivery systems are discussed, underscoring the importance of tailoring gene editing approaches to individual patient needs (A. Abdelnour et al., 2021). The review also addresses the ongoing clinical trials utilizing CRISPR technologies, which represent significant steps toward practical applications in treating genetic disorders (Min Lim & Henry Kim, 2022). **Conclusion:** In conclusion, the literature underscores the promise of CRISPR/Cas9 technology in revolutionizing the treatment landscape for monogenic neuromuscular diseases, while also emphasizing the critical need for rigorous preclinical studies to evaluate long-term safety and efficacy. The synthesis of findings from various articles illustrates both the advancements made and the hurdles that remain, calling for continued research to refine these innovative therapies for broader clinical application.

Keyword: Genome Editing, Monogenic Neuromuscular Diseases

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The exploration of genome editing technologies has rapidly advanced the field of gene therapy, particularly for monogenic neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The foundational work by (L Maeder & A Gersbach, 2016) highlights the significant progress made in gene delivery systems and cell transplantation, which have opened new avenues for treating neuromuscular disorders. Their examination of genome editing's potential to repair the dystrophin gene underscores the urgency of addressing DMD, a disease currently lacking approved therapies. However, they also note the limitations in these strategies, particularly regarding their applicability to a broader patient population and the unpredictability of editing outcomes.

Building on these insights, (Gaskell1 & Abualhaj2, 2018) delve into the CRISPR/Cas9 system, a transformative tool in the realm of targeted gene editing. They emphasize the advantages of CRISPR/Cas9 over traditional methods, such as ZFN and TALEN, particularly its efficiency and cost-effectiveness. The authors detail the dual pathways for DNA repair—NHEJ and HDR—highlighting the potential for heritable genome modifications, which could revolutionize treatment strategies for genetic diseases.

(You et al., 2019) further contextualize CRISPR/Cas9's application by presenting evidence from animal studies that demonstrate its efficacy in rectifying mutations associated with genetic diseases, including DMD. Their findings indicate that while initial results are promising, the long-term safety and effectiveness of CRISPR/Cas9 in humans remain critical concerns that necessitate further investigation.

(W. Kotagama et al., 2019) expand on the concept of genomic medicine, asserting that the ability to rectify specific genetic mutations through gene therapy represents a new frontier in treating human diseases. They discuss the fundamental mechanisms of gene editing and the various platforms available, positioning

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

CRISPR/Cas9 as a particularly accessible and effective option for addressing monogenic disorders.

In a focused analysis of DMD, (Mollanoori et al., 2020) report on the long-term effects of AAV vector-based CRISPR genome editing in canine models. Their study reveals sustained restoration of dystrophin expression over one year, although they caution against potential immunological responses and unintended genome modifications. The authors emphasize the necessity for rigorous preclinical studies to ensure the safety and efficacy of these therapies in human patients.

(A. Abdelnour et al., 2021) address the challenges posed by unique patient mutations in the context of CRISPR/Cas9 interventions. They highlight innovative approaches to gene modification for conditions like phenylketonuria (PKU) and muscular dystrophy, focusing on the potential of AAV vectors to deliver CRISPR/Cas9 effectively. Their findings underscore the importance of optimizing delivery systems to enhance in vivo editing efficiency and minimize off-target effects.

(Min Lim & Henry Kim, 2022) provide a comprehensive overview of CRISPR-based genome editing, detailing the evolution of genetic diagnostics and the therapeutic possibilities that have emerged from these advancements. They underscore the clinical potential of CRISPR technologies, which are increasingly being tested in human trials, marking a significant step toward practical applications in treating genetic disorders.

Finally, (Li et al., 2022) encapsulate the advancements made in the treatment of DMD through CRISPR/Cas9, noting the integration of this technology into viral vectors to improve skeletal muscle function in animal models. Their review of historical developments in gene editing for DMD emphasizes the ongoing efforts to refine these strategies, despite challenges related to histological improvements and hemodynamic outcomes.

This literature review synthesizes the evolving landscape of genome editing technologies, particularly CRISPR/Cas9, in addressing monogenic neuromuscular

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

diseases. Through critical analysis of the contributions from various authors, it highlights the promise and challenges inherent in translating these innovations into effective clinical therapies.

LITERATURE REVIEW

The article "Genome-editing Technologies for Gene and Cell Therapy" by Maeder and Gersbach (L Maeder & A Gersbach, 2016) provides a comprehensive overview of the advancements in gene delivery and cell transplantation, particularly in the context of treating neuromuscular disorders such as Duchenne Muscular Dystrophy (DMD). The authors emphasize the significance of genome editing as a promising approach for addressing the challenges posed by large deletions in the dystrophin gene, which is responsible for DMD.

One of the key insights presented in the article is the limitation of traditional viral delivery vectors due to the large size of the dystrophin gene, which hinders effective gene therapy. The authors highlight that while gene editing techniques have shown potential in repairing the dystrophin gene, the current strategies are still in developmental stages and may not be universally applicable to all patients with DMD. This is a critical point, as it underscores the necessity for ongoing research to refine these techniques to achieve predictable and reliable editing outcomes for a broader patient demographic.

The article also discusses early proof-of-principle experiments that demonstrated the feasibility of gene editing to restore dystrophin protein expression in cultured cells derived from DMD patients. While these findings are promising, the authors caution that the initial successes in vitro do not always translate to effective treatments in vivo. This distinction is vital for the field, as it highlights the gap between laboratory research and clinical application, suggesting that further studies are needed to evaluate the long-term efficacy and safety of these genome editing approaches.

Moreover, Maeder and Gersbach (L Maeder & A Gersbach, 2016) point out that, despite the advancements in genome editing technologies, there remains a lack of

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

approved therapies for DMD, which emphasizes the urgency for innovative solutions in this area. The article effectively captures the current landscape of gene and cell therapy for neuromuscular diseases, while also recognizing the hurdles that must be overcome to translate these scientific advancements into viable clinical options.

The article "Advances in Gene Therapy for Human Genetic Diseases Based on Crispr/Cas9 Gene Editing Technology" by Gaskell and Abualhaj (Gaskell1 & Abualhaj2, 2018) provides a comprehensive overview of the CRISPR/Cas9 system as a transformative tool for gene editing, particularly in the context of human genetic diseases. The authors effectively articulate the advantages of CRISPR/Cas9 over previous gene editing technologies such as Zinc Finger Nucleases (ZFN) and Transcription Activator-Like Effector Nucleases (TALEN), highlighting its simplicity, efficiency, cost-effectiveness, and capability for multi-target editing.

The article delineates the mechanism of CRISPR/Cas9, which utilizes sequence-specific single-guide RNA (sgRNA) to direct the Cas9 nuclease to specific genomic locations, facilitating precise double-stranded breaks. The subsequent repair of these breaks can occur via two primary pathways: Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR). The authors detail how NHEJ often results in insertions or deletions that can disrupt gene function, while HDR allows for more precise modifications through the use of exogenous templates. This distinction is crucial for understanding the potential applications of CRISPR/Cas9 in treating monogenic neuromuscular diseases, where accurate gene correction is often necessary.

The review also emphasizes the heritable nature of genomic modifications achieved through CRISPR/Cas9, which is particularly significant for addressing genetic disorders that are passed through generations. This characteristic underscores the potential for long-term therapeutic solutions for patients with monogenic diseases, offering hope for conditions that currently lack effective treatments.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

However, while the article provides a robust summary of the technological advancements and mechanisms involved in CRISPR/Cas9 gene editing, it could benefit from a more critical discussion on the ethical implications and potential off-target effects associated with this technology. The authors mention the efficiency of CRISPR/Cas9 but do not thoroughly address the risks of unintended genomic alterations, which are vital considerations in clinical applications.

The article "Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research" by You et al. (You et al., 2019) provides a comprehensive overview of the progress and challenges associated with the application of CRISPR-Cas9 technology in the context of genetic diseases, particularly focusing on monogenic disorders such as Duchenne muscular dystrophy (DMD) and others. The authors highlight significant advancements in the therapeutic application of CRISPR-Cas9, emphasizing its potential in rectifying pathogenic mutations that lead to various genetic conditions.

One of the key insights from the article is the demonstration of CRISPR-Cas9's therapeutic efficiency in preclinical models, particularly in small animals and some large animal studies. For instance, the authors note that the use of adeno-associated viruses for the intramuscular delivery of CRISPR components in dogs with DMD resulted in improved histological features of muscle tissue and partial restoration of dystrophin expression (You et al., 2019). This finding is crucial as it underlines the potential of CRISPR-Cas9 technology to address the molecular underpinnings of neuromuscular diseases, which often stem from single-gene mutations.

Furthermore, the article discusses the advancements made in gene editing within human embryos. The authors report a high targeting efficiency of CRISPR-Cas9 base editing in correcting mutations associated with Marfan syndrome and hypertrophic cardiomyopathy, noting that these interventions exhibited no mosaicism or off-target effects, which are critical considerations for clinical applications (You et al., 2019). This aspect of the research underscores the promise of CRISPR-Cas9 not only in somatic cells but also in germline editing, which could potentially prevent the transmission of genetic disorders to future generations.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

However, despite these promising results, the article also addresses the substantial hurdles that remain before CRISPR-Cas9 can be widely implemented in clinical settings. The authors caution that while short-term efficacy has been observed, the long-term safety and efficiency of these interventions in human patients must be rigorously evaluated. The potential for off-target effects and the ethical implications of germline editing are critical issues that necessitate careful consideration as research progresses (You et al., 2019).

The article titled "Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases" by Kotagama, Jayasinghe, and Abeysinghe (W. Kotagama et al., 2019) presents a comprehensive overview of the advancements in genomic medicine, particularly focusing on the applications of CRISPR technology in addressing monogenic disorders. The authors effectively elucidate the significance of understanding the genetic underpinnings of diseases, which has catalyzed substantial progress in biomedical research, particularly for conditions like Huntington's disease, cystic fibrosis, thalassemia, and sickle cell anemia.

One of the article's strengths lies in its detailed discussion of gene therapy's potential as a therapeutic strategy. The authors differentiate between gene replacement and gene editing, emphasizing that while the introduction of exogenous DNA can remediate defective genes, it is fraught with challenges such as off-target mutations. This critical evaluation of the limitations associated with traditional gene therapy sets the stage for discussing the advantages of gene editing technologies, particularly CRISPR/Cas9.

The article highlights the mechanism of CRISPR/Cas9, which operates through inducing double-strand breaks in the DNA and leveraging the cell's repair machinery to correct mutations. The authors commend the simplicity and precision of CRISPR/Cas9, attributing its prominence in the field of gene editing to its programmable nature, which enables site-specific alterations. This aspect is particularly relevant for the treatment of monogenic neuromuscular diseases, where precise gene editing can potentially rectify the underlying genetic defects.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

However, the authors do not shy away from addressing the ethical concerns and technical challenges associated with CRISPR technology. They point out the issues of reproducibility and the risks of off-target effects, which could lead to unintended genetic modifications. These concerns are particularly pronounced when considering the implications of editing the human germline, raising ethical questions that must be navigated as the technology advances.

The article "Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy" by Mollanoori et al. (Mollanoori et al., 2020) presents a comprehensive evaluation of the application of CRISPR/Cas9 technology in addressing Duchenne muscular dystrophy (DMD), a monogenic neuromuscular disorder. The authors effectively highlight the transformative potential of CRISPR/Cas9 in targeted genome editing, emphasizing its ease of use, flexibility, and efficiency, which have collectively invigorated interest in utilizing this technology for the treatment of various diseases, including monogenic disorders.

A significant aspect of the article is the focus on a long-term evaluation of AAV vector-based CRISPR genome editing. The study discussed demonstrates the ability to excise exon 23 of the dystrophin gene in mdx mice, with results indicating sustained restoration of dystrophin expression for at least one year following a single administration. This finding is particularly noteworthy as it suggests the potential for long-lasting therapeutic effects, which is crucial for conditions like DMD where muscle degeneration can lead to severe disability.

However, the authors also address critical concerns associated with the application of CRISPR/Cas9 technology, notably the host response to Cas9 and the occurrence of unintended genome modifications. The identification of these off-target effects is essential, as they pose significant challenges for the clinical application of genome editing technologies. The article underscores the necessity for further studies to minimize these off-target effects and to assess the long-term safety and efficiency of the treatment in larger animal models before transitioning to human trials.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The authors advocate for a more extensive exploration of the immunological responses to both the Cas9 nuclease and the dystrophin protein, which are vital for understanding the full implications of CRISPR/Cas9 therapy in clinical settings. Additionally, the call for optimization of delivery and gene editing strategies to enhance the proportion of intended gene modifications is a critical point that reflects the ongoing need for refinement in therapeutic approaches.

The article titled "The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases" by Abdelnour et al. (A. Abdelnour et al., 2021) provides a comprehensive examination of the applications and limitations of CRISPR/Cas9 technology in the treatment of monogenic neuromuscular diseases, particularly focusing on conditions such as phenylketonuria (PKU) and Duchenne muscular dystrophy (DMD). The authors emphasize the innovative potential of gene editing while also addressing the challenges posed by the necessity for patient-specific guide RNAs due to unique mutations.

One of the key insights presented in the article is the approach of utilizing liver tropic recombinant adeno-associated virus (AAV) vectors to deliver CRISPR/Cas9 for PKU treatment. This strategy aims to enhance neurological safety while allowing for normal dietary intake of phenylalanine, which is crucial for patient quality of life. The authors highlight that this method of gene modification not only addresses the metabolic aspects of PKU but also represents a significant advancement in gene therapy.

The article further explores the application of CRISPR/Cas9 in DMD, detailing the work of Ousterout et al. who utilized single or multiplexed sgRNAs to repair the dystrophin reading frame in human myoblasts. The findings from their in vitro studies, which demonstrated restoration of dystrophin expression, underscore the potential of this gene editing technology to rectify genetic defects at the cellular level. Additionally, the authors reference in vivo studies where genetically modified patient cells were transplanted into immune-deficient mice, resulting in the presence of human dystrophin, thus providing a promising avenue for future therapeutic strategies.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

Bengtsson et al.'s contributions to the field are also mentioned, particularly their methods involving the mutation in dystrophic mdx4cv mice using dual AAV vector/Cas9 systems. This research illustrates the precision of gene editing facilitated by Cas9 technology, which can effectively target specific mutations or correct entire genes. The article notes that the muscle-restricted delivery of Cas9 enhances the specificity and efficacy of the editing process, which is critical in avoiding off-target effects that can arise from gene editing.

Moreover, the authors discuss the necessity of high doses of AAV for effective in vivo genome editing, as evidenced by the work of Zhang et al. Their findings indicate that systemic administration of a dual AAV system—packaging Cas9 nuclease and sgRNA—can lead to significant improvements in dystrophin expression and muscle contractility in mouse models of DMD. This highlights the potential for CRISPR/Cas9 technology, particularly when combined with advanced delivery systems like scAAV, to revolutionize the treatment landscape for neuromuscular diseases.

The article titled "Basic Principles and Clinical Applications of CRISPR-Based Genome Editing" by Lim and Kim (Min Lim & Henry Kim, 2022) provides a comprehensive overview of the advancements in genome editing technologies, particularly focusing on CRISPR/Cas systems and their implications for treating genetic disorders, including monogenic neuromuscular diseases. The authors emphasize the significant impact of next-generation sequencing technologies, which have drastically lowered the costs associated with genetic diagnostics, thereby facilitating the identification of rare pathogenic mutations in clinical settings.

One of the key insights presented in the article is the rapid evolution of genome editing tools since the introduction of CRISPR/Cas systems in 2012. Lim and Kim highlight that these advancements have not only improved the efficiency and precision of genome editing but also expanded the potential applications in clinical settings. The authors discuss how CRISPR-based technologies offer hope for

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

patients with genetic disorders that currently lack effective treatments, thereby addressing a critical gap in medical therapies for such conditions.

The article also provides a critical evaluation of the ongoing clinical trials utilizing CRISPR-based genome editing for various human diseases. Lim and Kim assert that while the potential for these therapies is promising, it is essential to consider the ethical implications and safety concerns associated with genome editing. The authors argue that as these technologies progress, rigorous regulatory frameworks and ethical guidelines will be necessary to ensure that the benefits of genome editing are realized without compromising patient safety or ethical standards.

The article "CRISPR/Cas systems usher in a new era of disease treatment and diagnosis" by Li et al. (Li et al., 2022) provides a comprehensive overview of the application of CRISPR/Cas9 gene editing technology in the context of neuromuscular disorders, particularly focusing on Duchenne muscular dystrophy (DMD). DMD is characterized by mutations in the dystrophin gene, which are responsible for the absence of a functional dystrophin protein, leading to severe muscle degeneration and associated complications.

The authors detail the challenges posed by the large size of the dystrophin gene, which complicates its delivery via conventional viral vectors. This limitation is particularly significant given the critical nature of the dystrophin protein in maintaining muscle integrity. The incorporation of CRISPR/Cas9 into viral vectors represents a significant advancement in therapeutic strategies for DMD, as it allows for precise editing of the gene responsible for the disorder.

The article highlights several key studies that have utilized the CRISPR/Cas9 system to target specific exons within the dystrophin gene. For instance, the use of AAV9 vectors to deliver gene-editing components has shown promise in restoring dystrophin expression in both cardiac and skeletal muscle in animal models. This approach has been further refined with the development of specific CRISPR/Cas9-HCAdV vectors, which have demonstrated enhanced efficiency in delivering CRISPR components.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

However, despite these advancements, the article also critically evaluates the limitations of current methodologies. For example, while AAV-mediated CRISPR gene editing has shown the potential to restore dystrophin levels, the authors note that improvements in histological and hemodynamic parameters have not been consistently observed. This discrepancy raises important questions about the long-term efficacy of such treatments and the need for further optimization of vector doses and delivery mechanisms.

Moreover, the depletion of guide RNA (gRNA) vectors has been identified as a significant barrier to the success of AAV-mediated CRISPR therapies. This finding underscores the necessity for ongoing research to enhance the stability and delivery of gRNA, which is crucial for achieving sustained therapeutic effects.

CONCLUSION

The literature review presents a comprehensive analysis of the advancements and challenges in genome editing technologies, particularly focusing on CRISPR/Cas9, in the context of monogenic neuromuscular diseases such as Duchenne muscular dystrophy (DMD). The introduction outlines the urgency of developing effective treatments for DMD, a condition currently lacking approved therapies, and highlights the foundational work in gene delivery systems that has paved the way for innovative therapeutic strategies (L Maeder & A Gersbach, 2016).

The review systematically discusses the transformative potential of CRISPR/Cas9 technology, emphasizing its efficiency and cost-effectiveness compared to traditional gene editing methods (Gaskell1 & Abualhaj2, 2018). The dual pathways for DNA repair—Non-Homologous End Joining (NHEJ) and Homology Directed Repair (HDR)—are articulated, with the former often leading to unpredictable outcomes, while the latter offers more precise modifications, crucial for addressing genetic disorders (You et al., 2019). The review further highlights promising results from animal studies, which demonstrate the efficacy of CRISPR/Cas9 in rectifying mutations associated with genetic diseases, although concerns regarding long-term

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

safety and off-target effects persist [ref: 9b33efa7-2013-41d8-9962-010ac2c15860; ref: 833ce712-060f-4e32-b38c-cd7fd048e774].

Moreover, the challenges posed by unique patient mutations and the necessity for optimized delivery systems are discussed, underscoring the importance of tailoring gene editing approaches to individual patient needs (A. Abdelnour et al., 2021). The review also addresses the ongoing clinical trials utilizing CRISPR technologies, which represent significant steps toward practical applications in treating genetic disorders (Min Lim & Henry Kim, 2022).

In conclusion, the literature underscores the promise of CRISPR/Cas9 technology in revolutionizing the treatment landscape for monogenic neuromuscular diseases, while also emphasizing the critical need for rigorous preclinical studies to evaluate long-term safety and efficacy. The synthesis of findings from various articles illustrates both the advancements made and the hurdles that remain, calling for continued research to refine these innovative therapies for broader clinical application.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. L Maeder, M. & A Gersbach, C., 2016. Genome-editing Technologies for Gene and Cell Therapy. ncbi.nlm.nih.gov
2. Gaskell1, D. & Abualhaj2, M., 2018. Advances in Gene Therapy for Human Genetic Diseases Based on Crispr/Cas9 Gene Editing Technology. [PDF]

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

3. You, L., Tong, R., Li, M., Liu, Y., Xue, J., & Lu, Y., 2019. Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. ncbi.nlm.nih.gov
4. W. Kotagama, O., D. Jayasinghe, C., & Abeysinghe, T., 2019. Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases. ncbi.nlm.nih.gov
5. Mollanoori, H., Rahmati, Y., Hassani, B., Havasi Mehr, M., & Teimourian, S., 2020. Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy. ncbi.nlm.nih.gov
    A. Abdelnour, S., Xie, L., A. Hassanin, A., Zuo, E., & Lu, Y., 2021. The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. ncbi.nlm.nih.gov
6. Min Lim, J. & Henry Kim, H., 2022. Basic Principles and Clinical Applications of CRISPR-Based Genome Editing. ncbi.nlm.nih.gov
7. Li, R., Wang, Q., She, K., Lu, F., & Yang, Y., 2022. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved